Translating ALC1 Inhibition into Clinical Success: Targeting Genomic Instability
Time: 11:00 am
day: Day Two
Details:
- Leveraging EIS-12656 to disrupt chromatin remodeling and exploit vulnerabilities in tumors with impaired DNA repair mechanisms
- Demonstrating rapid tumor inhibition and strong tolerability in preclinical models
- Highlighting the drug’s translational potential
